Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in 3 Cases of Tyrosinemia

Naser Honar--- Department of Pediatrics Gastroenterology and Hepatology, Shiraz University of Medical Sciences, Shiraz, Iran,
Nader Shakibazad--- Department of Pediatrics Hematology and Oncology, Shiraz University of Medical Sciences,
Zahra Serati Shirazi--- Department of Pediatrics Intensive Care Units, Shiraz University of Medical Sciences, Shiraz, Iran,
Seyed Mohsen Dehghani--- Department of Pediatrics Gastroenterology and Hepatology, Shiraz University of Medical Sciences, Shiraz, Iran,
Soroor Inaloo--- Department of Pediatrics Neurology, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract


8

Tyrosinemia Type 1 is a hereditary disorder with liver, kidney and nervous system involvement. We report 3 children developed diaphragmatic paralysis requiring mechanical ventilation after discontinuation of NTBC treatment. In patients with Tyrosinemia type 1, combined treatment with NTBC and a low-tyrosine diet have prevented neurological crises. Treatment with NTBC in the first months of life protects against hepatic and neurologic complications. Neurological crises can occur in tyrosinemia without treatment and also occur when treatment stops. We report three patients that developed diaphragmatic paralysis after interruption of NTBC treatment, which finally required mechanical ventilation. It should be emphasized that discontinuation of NTBC can induce diaphragmatic paralysis and respiratory failure. So we should advise patients to use NTBC for long term and not interrupted it.


Keywords


Tyrosinemia, Diaphragmatic Paralysis; NTBC; Neurological Crises

Full Text:

PDF

9

References


Schlump JU, Perot C, Ketteler K, Schiff M, Mayatepek E, Wendel U, et al. Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment. J Inherit Metab Dis. 2008;31 Suppl 2:S223-5.

de Laet C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L, et al. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis. 2013;8:8.

Lock E, Ranganath LR, Timmis O. The role of nitisinone in tyrosine pathway disorders. Curr Rheumatol Rep. 2014;16(11):014-0457.

Larochelle J, Alvarez F, Bussières JF, Chevalier I, Dallaire L, Dubois J, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Mol Genet Metab. 2012;107(1-2):49-54.

Santra S, Baumann U. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008;9(7):1229-36.

Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis. 2008;31(1):81-7.

Schlump JU, Mayatepek E, Spiekerkoetter U. Significant increase of succinylacetone within the first 12 h of life in hereditary tyrosinemia type 1. Eur J Pediatr. 2010;169(5):569-72.




DOI: http://dx.doi.org/10.22037/ijcn.v11i4.11182

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Iranian Journal of Child Neurology